Free Hindi Comics Velamma All 87 ambirica
WhatsApp: Category:Year of birth missing (living people) Category:Living people Category:Indian film actressesComparison of alpha-linolenic acid and arachidonic acid in the prevention of nonalcoholic fatty liver disease and insulin resistance: a randomized trial. Nonalcoholic fatty liver disease (NAFLD) is a major risk factor for type 2 diabetes and coronary heart disease. The lipid omega-3 fatty acid alpha-linolenic acid (ALA) might be protective against NAFLD, but previous intervention studies are equivocal. This study compared the effect of ALA and arachidonic acid (ARA) on NAFLD and insulin resistance. The sample size was determined by power analysis for the primary end point of NAFLD evaluated by liver ultrasound. As an exploratory end point, the main focus of this trial was on insulin resistance (IR), as determined by homeostasis model assessment (HOMA). A randomized, double-blind, placebo-controlled trial was conducted among a cohort of 105 patients with NAFLD and with increased BMI or waist circumference. Subjects were randomized to ALA or ARA, which were provided as a dietary supplement (5.2 g/d) for 12 weeks. The primary end point of NAFLD was not achieved, but a significant decrease of liver fat was seen in both treatment groups. The change in liver fat was -16.4% in the ALA group and -6.1% in the ARA group. The treatment groups did not differ significantly. However, the reduction in liver fat in the ALA group was positively associated with dietary ALA intake, as reflected by the differences in ΔALA and ΔARA (Spearman's ρ = 0.57, P = 0.0013). The 12-week treatment with either ALA or ARA had no effect on IR, but HOMA-IR increased significantly in both groups (P = 0.0002), probably reflecting an increase in muscle insulin sensitivity. The 12-week dietary supplementation of ALA or ARA had no effect on IR or on the major anthropometric measures of obesity. However, a significant reduction of liver fat was seen in the ALA group, and this was associated with higher dietary intake. The reduction of liver fat in the ALA group was positively associated with baseline dietary ALA intake, suggesting that increasing ALA intake could be a treatment strategy for NAFLD in humans.